The effect of corticosteroids on the gastric mucosa in patients with pernicious anemia is of particular interest in view of the possibility that atrophic gastritis, the primary pathologic lesion in pernicious anemia, may result from destruction of gastric glands by an autoimmune process (1) .
The first observation which suggested that corticosteroids might enhance vitamin B12 absorption in patients with pernicious anemia was made by Doig, Girdwood, Duthie, and Knox (2) . Three of four patients treated with prednisolone exhibited a hematologic response with a reticulocytosis, an increase in hemoglobin and red blood cell count, and correction of the megaloblastic to normoblastic erythropoiesis. In several studies that were stimulated by this observation, it was suggested alternatively that prednisolone enhanced vitamin B12 absorption in the absence of intrinsic factor (3) and that prednisolone stimulated the gastric secretion of intrinsic factor in these patients (4, 5) . Kristensen and Friis (6) proved that the latter mechanism was responsible for the increase in vitamin B12 absorption during corticosteroid therapy. They found that gastric juice collected from pernicious anemia patients with enhanced vitamin B12 absorption during therapy with prednisolone contained intrinsic factor on in vivo assay.
There have been no studies correlating gastric secretion with gastric mucosal histology during corticosteroid therapy in patients with pernicious anemia. In the present investigation, gastric mucosal histology, gastric secretion of acid and intrinsic factor, vitamin B12 absorption, and the titers of circulating antibodies to gastric parietal cell cytoplasm and intrinsic factor were studied 'before and during a period of prednisolone therapy in patients with pernicious anemia or atrophic gastritis.
In response to prednisolone therapy, parietal and chief cells reappeared in the gastric mucosa of three patients with pernicious anemia, in one patient with latent pernicious anemia, and in a patient with atrophic gastritis. Intrinsic factor was present in the gastric juice of each of these patients during steroid therapy, and acid was detected in stimulated secretion in three patients. There was an improvement in vitamin B12 absorption in four of the patients with pernicious anemia and in the patient with latent pernicious anemia. The patients who responded to prednisolone therapy were those whose sera exhibited the highest titers of parietal cell antibody. The response of one patient (No. 1) with pernicious anemia to prednisolone therapy has been reported previously (7) .
Methods
Patients. Studies were carried out on six patients with pernicious anemia who were in hematologic remission, one patient with latent pernicious anemia, and one patient with atrophic gastritis without pernicious anemia. The pertinent clinical and laboratory data on these patients are summarized in Table I .
The criteria upon which the diagnosis of pernicious anemia was based were a megaloblastic anemia that responded to vitamin B,2 therapy, a subnormal Schilling test corrected with hog intrinsic factor, and an absence of acid and intrinsic factor in gastric juice collected 803 (8) .
Gastric mucosal biopsy. Gastric mucosal biopsies were obtained from the body and fundus of the stomach through a hydraulic multiple biopsy tube positioned fluoroscopically (9) . Forty-eight biopsy specimens were obtained for light microscopic study, twenty before prednisolone therapy and twenty-eight during therapy. Each biopsy 1 Histalog, Eli Lilly, Indianapolis, Ind.
tamin B12-60Co. B12 = Schilling test with vitamin B12 alone; B12-I.F. = specimen was mounted on filter paper, fixed in formalin, embedded in paraffin, and sectioned at 6 /A at right angles to the surface of the mucosa; the serial sections were stained with hematoxylin and eosin. Coded slides were prepared so that the microscopist was unaware of the patient's name or prednisolone therapy. The type of cell present in the gastric glands and the extent of intestinal metaplasia were assessed; in particular, the presence or absence of chief and parietal cells was noted.
Vitamin Bs absorption. A modification of the Schilling test was used (10) . The 48-hour urinary excretion of a test dose of 0.2 lzg of 'Co-labeled vitamin B,2 (Bla'-Co) was measured. In normal subjects more than 10% of the administered dose was excreted in the urine.
Parietal cell and intrinsic factor antibody assays. Sera obtained from each patient before and during the period of prednisolone therapy were stored at -20°C without added preservative. Parietal cell antibody titers were measured by an immunofluorescent technique with freshfrozen sections of rat gastric mucosa and fluoresceinlabeled antihuman yG-globulin antiserum (11) . Intrinsic factor antibody was assayed by the method of Jeffries, Hoskins, and Sleisenger (12) .
Prednisolone therapy. Each patient was initially hospitalized for assessment. Analyses of gastric secretion, gastric biopsies, and vitamin B,2 absorption tests were performed, and serum was obtained for antibody assays. Prednisolone in doses varying from 10 to 40 mg was then given daily by mouth for periods of 2 to 8 months, and the above studies were repeated during the period of therapy. Patients with pernicious anemia continued to receive monthly injections of vitamin B12 (100 ug, intramuscularly) during the period of steroid therapy. (Figure 2a, insert; Figure 3a) . A few parietal cells were identified in sections from one of five biopsy specimens obtained from one patient with pernicious anemia (No. 1, reference 7) and in one of the two biopsy specimens from the patient with atrophic gastritis (No. 8, Figure  3a) ; many of these cells in the latter biopsy appeared to be degenerating. Localized areas of intestinal metaplasia were present in many of the sections ( Figures la, 2a) ; this metaplasia was more extensive in biopsies from three of the patients with pernicious anemia (No. 4, 5, and 6, Figure 4a ). In each mucosal biopsy specimen the lamina propria was infiltrated with lymphocytes, plasma cells, and eosinophils, and in two biopsy specimens there was a lymphoid follicle (Figure 2a) .
PREDNJSOLONE IN PERNICIOUS ANEMIA
During prednisolone therapy, parietal cells were identified in each of the 15 biopsy specimens obtained from five patients (No. 1, 2, 3, 7, and 8). These cells were recognized by their eosinophilic staining and by their intracellular secretory canaliculi (Figures lb, 2b, 3b) . Gland body in the sera of seven patients. In one patient (No. 8), however, who received 40 mg of prednisolone daily, there was a significant decrease in parietal cell antibody titer from 1/512 before therapy to 1/64 during therapy (Table IV) . The titers of intrinsic factor antibody, present in sera from two patients (No. 1 and 7), decreased during prednisolone therapy.
Patients with the higher serum titers of parietal cell antibody were those who exhibited changes in gastric secretion, vitamin B12 absorption, or gastric mucosal histology during prednisolone therapy. Discussion Regardless of etiology, gastric mucosal atrophy characterized by an absence of parietal and chief cells in the gastric glands must result from a derangement of cell turnover in the mucosa. Either the capacity of the mucosa to regenerate gastric parietal and chief cells is reduced, or these cells or their precursors or both are destroyed at an increased rate. There is insufficient information relating to cell turnover in the glandular compartment of normal or atrophic human gastric mucosae to indicate which of these alternative mechanisms leads to mucosal atrophy in patients with pernicious anemia.
In the present study it has been shown that patients with pernicious anemia or atrophic gastritis may respond to prednisolone therapy. This response is characterized by an enhancement of vitamin B12 absorption (3, 5, 6) , secretion of acid and intrinsic factor (6) , and the reappearance of parietal and chief cells in the previously atrophic gastric mucosa; the improvement in gastric secretory function is thus the result of parietal cell regeneration rather than a stimulation of residual parietal cells in the atrophic mucosa.
In three of the patients who responded to prednisolone therapy (No. 1, 2, and 8) , the reappearance of parietal cells in the mucosa was accompanied by acid and intrinsic factor secretion. In two patients, however, parietal cells were demonstrated in mucosal biopsies, but stimulated gastric juices contained intrinsic factor without acid (No. 3 and 7) . In these patients with a small parietal cell population, the analysis of stimulated gastric juice for acid may be an insensitive test for parietal cell secretion. Hydrogen ions may be actively reabsorbed by metaplastic intestinal epithelial cells in the gastric mucosa or may diffuse from the gastric lumen through the damaged mucosa (13) .
It is evident from our study that atrophic gastritis in patients with pernicious anemia is not due to a loss of the mucosal potential to regenerate parietal and chief cells. The mechanism of the steroid effect remains uncertain; the regeneration of gastric glands during therapy may have been due to a potentiation of cell regeneration or an inhibition of cell destruction in the mucosa. Animal studies, however, suggest that the latter mechanism may be operative; in experimental animals, adrenalectomy increases mitotic activity (14, 15) , whereas corticosteroid administration decreases cell division in the gastric mucosa (16, 17) .
The hypothesis that gastric mucosal glands in the body and fundus are selectively destroyed by autoimmune processes and that parietal cell regeneration may result from the immunosuppressive action of prednisolone is unproven. Although parietal cell and intrinsic factor antibodies are usually associated with chronic atrophic gastritis or pernicious anemia (18) , there is no evidence that these antibodies are cytotoxic to gastric parietal cells; the regeneration of parietal cells in prednisolone-treated patients who exhibited no decrease in the serum titer of parietal cell antibody is evidence to the contrary. It is of interest, however, that patients who responded to prednisolone therapy were those with higher titers of circulating parietal cell antibody. High titers of parietal cell antibody, persisting for many years after the diagnosis of pernicious anemia has been established (11, 18) , may reflect a continuing stimulation of antibody production by parietal cell antigen released from degenerating mucosal cells. The three patients who did not respond to prednisolone therapy had low titers of parietal cell antibody and exhibited extensive intestinal metaplasia in their gastric mucosal biopsies. Widespread intestinal metaplasia may not only limit the mucosal potential to regenerate parietal cells, but may also lower the titer of circulating parietal cell antibody by decreasing the turnover of parietal cells, parietal cell precursors, or both in the mucosa.
The changes in gastric secretion, vitamin B12 absorption, and mucosal histology during prednisolone therapy cannot be attributed to a decrease in the titer of intrinsic factor antibody first demonstrated by Taylor (19) . Two patients who responded to therapy exhibited a decrease in the titer of intrinsic factor antibody; this antibody was not present, however, in sera from the other patients who were studied.
The role of autoimmune mechanisms in the pathogenesis of atrophic gastritis and pernicious anemia may be clarified when cell regeneration has been studied in the glandular compartment of normal and atrophic gastric mucosae. The effects of corticosteroids on gastric mucosal histology in pernicious anemia must be correlated not only with autoimmune phenomena, but also with cell regeneration and destruction in the mucosa.
Summary
The effects of prednisolone therapy on gastric mucosal histology, gastric secretion of acid and intrinsic factor, vitamin B12 absorption, and the serum titers of antibody to intrinsic factor and gastric parietal cell cytoplasm were studied in six patients with pernicious anemia, one patient with latent pernicious anemia, and one patient with atrophic gastritis.
Prednisolone therapy enhanced vitamin B12 absorption (as measured by the Schilling test) in four patients with pernicious anemia and in the patient with latent pernicious anemia; absorption remained normal in the patient with atrophic gastritis. In five patients (three with pernicious anemia, one with latent pernicious anemia, and one with atrophic gastritis), gastric glands containing parietal and chief cells were identified in mucosal biopsies during the steroid therapy. The reappearance of parietal cells in the mucosa was associated with acid secretion in three patients and with intrinsic factor secretion detected by an in vitro assay technique in each of the five patients. The serum titers of parietal cell antibody remained constant in seven patients during steroid therapy; in one patient who received the highest daily dose of prednisolone (40 mg), the titer of this antibody decreased. There was a decrease in the titers of intrinsic factor antibody in two patients. This study indicates that the atrophic gastric mucosa in patients with pernicious anemia may retain its potential to regenerate parietal cellsthat atrophy is not due to a loss of regenerative potential. Regeneration was seen in patients with the higher titers of parietal cell antibody and did not occur in patients with low titers who also exhibited extensive intestinal metaplasia. It is suggested that persisting high titers of gastric parietal cell antibody in patients with pernicious anemia may be stimulated by the release of antigen from degenerating cells in atrophic gastric glands.
Addendum
In a recent publication, Ardeman and Chanarin (20) confirmed the results of the present study. Seven of eight patients with pernicious anemia treated with 30 or 40 mg of prednisone daily for 3 to 5 weeks exhibited an improvement in vitamin B12 absorption. Intrinsic factor secretion was increased in four of five patients, and acid was detected in gastric juice from two of seven patients. Parietal and chief cells were demonstrated in gastric mucosal biopsies from two patients. The authors observed that there was no relation between the response to steroids and the presence of intrinsic factor antibody in the patients' sera.
